Novo Nordisk, Inc. operates a healthcare company focusing on diabetes care. The company manufactures a line of human insulin and insulin analog products for individuals with diabetes. It also offers products and services for therapeutic areas, such as bleeding episodes in people with hemophilia who have inhibitors; human growth hormone and advanced delivery systems that include cartridges for children with short stature due to growth hormone deficiency; and hormone therapy products for women. In addition, the company operates a research center for biopharmaceutical research projects; and to build the clinical pipeline of products for the treatment of chronic inflammatory diseases. It offers ...
100 College Road West
Princeton, NJ 08540
Founded in 1982
Novo Nordisk Promotes Eddie Williams to Senior Vice President of Biopharmaceuticals, Effective February 1, 2014
Jan 30 14
Novo Nordisk announced the promotion of Eddie Williams to senior vice president of biopharmaceuticals, effective February 1, 2014. Eddie brings three decades of experience in the pharmaceutical industry. He joined Novo Nordisk in 2006 and currently serves as the corporate vice president of biopharmaceuticals. In this capacity, he leads the sales and marketing, business development and new product commercialization functions for the company's growing U.S. biopharmaceuticals business, which develops medicines for people with hemophilia, as well as various types of hormone deficiencies.
Novo Nordisk, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Provides Earnings Guidance for the Year 2013 and 2014
Oct 31 13
Novo Nordisk, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported sales of DKK 20,511 million compared to DKK 19,845 million a year ago. Operating profit was DKK 7,992 million compared to DKK 7,864 million a year ago. Profit before income taxes was DKK 8,299 million compared to DKK 7,359 million a year ago. Net profit was DKK 6,415 million compared to DKK 5,667 million a year ago. Capital expenditure was DKK 908 million compared to DKK 942 million a year ago. Net cash generated from operating activities were DKK 6,217 million compared to DKK 7,962 million a year ago. Free cash flow was DKK 5,219 million compared to DKK 6,926 million a year ago. Diluted earnings per share/ADR were DKK 11.96 compared to DKK 10.33 a year ago.
For the nine months, the company reported sales of DKK 61,874 million compared to DKK 57,064 million a year ago. Operating profit was DKK 24,139 million compared to DKK 21,902 million a year ago. Profit before income taxes was DKK 24,749 million compared to DKK 20,359 million a year ago. Net profit was DKK 19,131 million compared to DKK 15,677 million a year ago. Diluted earnings per share/ADR were DKK 35.39 compared to DKK 28.32 a year ago. Net cash generated from operating activities were DKK 20,570 million compared to DKK 20,700 million a year ago. Purchase of property, plant and equipment was DKK 2,478 million compared to DKK 2,330 million a year ago.
For 2013, expectations to operating performance in local currencies are unchanged. Sales growth measured in local currencies is expected to be 11%-13% and operating profit growth measured in local currencies is expected to be 12%-15%.
The preliminary outlook for 2014 indicates high single-digit growth in sales and operating profit, both measured in local currencies.
Novo Nordisk, Inc. to Report Fiscal Year 2013 Results on Jan 30, 2014
Oct 31 13
Novo Nordisk, Inc. announced that they will report fiscal year 2013 results on Jan 30, 2014